症例報告: アルツハイマー病のパラドックス: 臨床的に安定した記憶喪失症候群で,完全なバイオマーカー陽性性と最小限のイメージング証拠
Anna-Chloé Balageas1, Johnny Vercouillie2, Nicolas Arlicot2,3
1Centre Mémoire Ressources et Recherche CHU Tours, Tours, France.
Frontiers in medicine
|September 4, 2025
まとめ
アルツハイマー病 (AD) のバイオマーカーを持つ75歳の患者は,15年間安定した記憶喪失を示しました. 限られたアミロイドとPETスキャンでのタウ,炎症,または低代謝は,ADのバイオマーカーのみの予測値に異議を唱えます.
科学分野:
- 神経学
- 神経変性疾患
- アルツハイマー病の研究
背景:
- アルツハイマー病 (AD) の特徴は 認知能力の低下です
- 脳脊髄液 (CSF) のバイオマーカーはしばしばADの病理性を示す.
- バイオマーカーの陽性性と臨床進行の関係は異なる.
研究 の 目的:
- ADのバイオマーカーにもかかわらず,長期的な臨床安定性のユニークなケースを提示します.
- 連続PET画像を用いてADの病変の進行を調査する.
- バイオマーカーの証拠とADの臨床経路の間の解離を調査する.
主な方法:
- 記憶喪失症候群の15年の歴史を持つ75歳の患者のケーススタディ
- アルツハイマー病 (AD) のバイオマーカーに対する脳脊髄液 (CSF) の分析
- アミロイド,タウ,代謝,神経炎症を評価するために2年連続のポジートロン放出トモグラフィー (PET) 画像撮影.
主要な成果:
- 患者は15年間 臨床的に安定した 記憶喪失症候群を示した.
- CSFのプロフィールはアルツハイマー病 (AD) と強く一致しました.
- 連続PET画像は,限られたアミロイドの蓄積,有意なタウの蓄積,低代謝,および2年間の神経炎症を明らかにした.
結論:
- このケースは アルツハイマー病 (AD) の病理に対する 重要な個々の回復力を強調しています
- ADのバイオマーカーの陽性性と臨床進行の間の顕著な分離を示しています.
- この発見は,ADのバイオマーカーの孤立した予後値に疑問を投げかけています.
関連する概念動画
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Positive Symptoms Schizophrenia: Hallucinations and Delusions
1.1K
Schizophrenia is a complex psychiatric disorder characterized by a range of symptoms that significantly impact cognition, behavior, and emotional regulation. Among these, the positive symptoms stand out as they involve the addition or exaggeration of normal mental functions, deviating markedly from typical behavior and perception. Hallucinations and delusions are prominent positive symptoms, each profoundly affecting the individual's experience of reality.
Hallucinations
Hallucinations in...
Hallucinations
Hallucinations in...
1.1K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Huntington Disease l: Introduction
110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110


